{
    "title": "107_s215",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Medication Equity and Drug Savings \nAct''.\n\nSEC. 2. IMPORTATION OF COVERED PRODUCTS FOR PERSONAL USE.\n\n    (a) In General.--Chapter VIII of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 381 et seq.) is amended by adding at the end \nthe following:\n\n``SEC. 805. IMPORTATION OF COVERED PRODUCTS FOR PERSONAL USE.\n\n    ``(a) Definitions.--In this section:\n            ``(1) Covered product.--The term `covered product' means a \n        prescription drug described in section 503(b)(1).\n            ``(2) Foreign country.--The term `foreign country' means--\n                    ``(A) Australia, Canada, Israel, Japan, New \n                Zealand, Switzerland, and South Africa; and\n                    ``(B) any other country, union, or economic area \n                that the Secretary designates for the purposes of this \n                section, subject to such limitations as the Secretary \n                determines to be appropriate to protect the public \n                health.\n            ``(3) Market value.--The term `market value' means--\n                    ``(A) the price paid for a covered product in \n                foreign country; or\n                    ``(B) in the case of a gift, the price at which the \n                covered product is being sold in the foreign country \n                from which the covered product is imported.\n    ``(b) Importation in Person.--\n            ``(1) Regulations.--Notwithstanding subsections (d) and (t) \n        of section 301 and section 801(a), the Secretary shall \n        promulgate regulations permitting individuals to import into \n        the United States from a foreign country, in personal baggage, \n        a covered product that meets--\n                    ``(A) the conditions specified in paragraph (2); \n                and\n                    ``(B) such additional criteria as the Secretary \n                specifies to ensure the safety of patients in the \n                United States.\n            ``(2) Conditions.--A covered product may be imported under \n        the regulations if--\n                    ``(A) the intended use of the covered product is \n                appropriately identified;\n                    ``(B) the covered product is not considered to \n                represent a significant health risk (as determined by \n                the Secretary without any consideration given to the \n                cost or availability of such a product in the United \n                States); and\n                    ``(C) the individual seeking to import the covered \n                product--\n                            ``(i) states in writing that the covered \n                        product is for the personal use of the \n                        individual;\n                            ``(ii) seeks to import a quantity of the \n                        covered product appropriate for personal use, \n                        such as a 90-day supply;\n                            ``(iii) provides the name and address of a \n                        health professional licensed to prescribe drugs \n                        in the United States that is responsible for \n                        treatment with the covered product or provides \n                        evidence that the covered product is for the \n                        continuation of a treatment begun in a foreign \n                        country;\n                            ``(iv) provides a detailed description of \n                        the covered product being imported, including \n                        the name, quantity, and market value of the \n                        covered product;\n                            ``(v) provides the time when and the place \n                        where the covered product is purchased;\n                            ``(vi) provides the port of entry through \n                        which the covered product is imported;\n                            ``(vii) provides the name, address, and \n                        telephone number of the individual who is \n                        importing the covered product; and\n                            ``(viii) provides any other information \n                        that the Secretary determines to be necessary, \n                        including such information as the Secretary \n                        determines to be appropriate to identify the \n                        facility in which the covered product was \n                        manufactured.\n            ``(3) Importation by an individual other than the \n        patient.--The regulations shall permit an individual who seeks \n        to import a covered product under this subsection to designate \n        another individual to effectuate the importation if the \n        individual submits to the Secretary a certification by a health \n        professional licensed to prescribe drugs in the United States \n        that travelling to a foreign country to effectuate the \n        importation would pose a significant risk to the health of the \n        individual.\n            ``(4) Consultation.--In promulgating regulations under \n        paragraph (1), the Secretary shall consult with the United \n        States Trade Representative and the Commissioner of Customs.\n    ``(c) Importation by Mail.--\n            ``(1) Regulations.--Notwithstanding subsections (d) and (t) \n        of section 301 and section 801(a), the Secretary shall \n        promulgate regulations permitting individuals to import into \n        the United States by mail a covered product that meets such \n        criteria as the Secretary specifies to ensure the safety of \n        patients in the United States.\n            ``(2) Criteria.--In promulgating regulations under \n        paragraph (1), the Secretary shall impose the conditions \n        specified in subsection (b)(2) to the maximum extent \n        practicable.\n            ``(3) Consultation.--In promulgating regulations under \n        paragraph (1), the Secretary shall consult with the United \n        States Trade Representative and the Commissioner of Customs.\n    ``(d) Records.--Any information documenting the importation of a \ncovered product under subsections (b) and (c) shall be gathered and \nmaintained by the Secretary for such period as the Secretary determines \nto be appropriate.\n    ``(e) Study and Report.--\n            ``(1) Study.--The Secretary shall conduct a study on the \n        imports permitted under this section, taking into consideration \n        the information received under subsections (b) and (c).\n            ``(2) Evaluations.--In conducting the study, the Secretary \n        shall evaluate--\n                    ``(A) the safety and purity of the covered products \n                imported; and\n                    ``(B) patent, trade, and other issues that may have \n                an effect on the safety or availability of the covered \n                products.\n            ``(3) Report.--Not later than 5 years after the date of \n        enactment of this section, the Secretary shall submit to \n        Congress a report describing the results of the study.\n    ``(f) No Effect on Other Authority.--Nothing in this section limits \nthe statutory, regulatory, or enforcement authority of the Secretary \nrelating to importation of covered products, other than the importation \ndescribed in subsections (b) and (c).\n    ``(g) Limitation.--Information collected under this section shall \nbe subject to section 522a of title 5, United States Code.''.\n    (b) Conforming Amendment.--Section 801(d)(1) of the Federal Food, \nDrug, and Cosmetic Act (21 U.S.C. 381(d)(1)) is amended by striking \n``section 804'' and inserting ``sections 804 and 805''.\n\nSEC. 3. CORRECTION OF IMPEDIMENTS IN IMPLEMENTATION OF MEDICINE EQUITY \n              AND DRUG SAFETY ACT OF 2000.\n\n    (a) Access to Labeling to Permit Importation.--Section 804 of the \nFederal Food, Drug, and Cosmetic Act (21 U.S.C. 384) is amended--\n            (1) in subsection (b)--\n                    (A) in paragraph (2), by striking ``and'' at the \n                end;\n                    (B) in paragraph (3), by striking the period at the \n                end and inserting ``; and''; and\n                    (C) by adding at the end the following paragraph:\n            ``(4) specify a fair and reasonable fee that a manufacturer \n        may charge an importer for printing and shipping labels for a \n        covered product for use by the importer.'';\n            (2) in subsection (e)(2), by inserting after ``used only \n        for purposes of testing'' the following: ``or the labeling of \n        covered products''; and\n            (3) in subsection (h)--\n                    (A) by striking ``No manufacturer'' and inserting \n                the following:\n            ``(1) In general.--No manufacturer''; and\n                    (B) by adding at the end the following:\n            ``(2) No conditions for labeling.--No manufacturer of a \n        covered product may impose any condition for the privilege of \n        an importer in using labeling for a covered product, except a \n        requirement that the importer pay a fee for such use \n        established by regulation under subsection (b)(4).''.\n    (b) Prohibition of Pricing Conditions.--Paragraph (1) of section \n804(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 384(h)) \n(as designated by subsection (a)(3)(A)) is amended by inserting before \nthe period at the end the following: ``that--\n                    ``(A) imposes a condition regarding the price at \n                which an importer may resell a covered product; or\n                    ``(B) discriminates against a person on the basis \n                of--\n                            ``(i) importation by the person of a \n                        covered product imported under subsection (a); \n                        or\n                            ``(ii) sale or distribution by the person \n                        of such covered products''.\n    (c) Conditions for Taking Effect.--Section 804 of the Federal Food, \nDrug, and Cosmetic Act (21 U.S.C. 384) is amended by striking \nsubsection (l) and inserting the following:\n     ``(l) Conditions for Taking Effect.--\n            ``(1) In general.--Except as provided in paragraph (2), \n        this section shall become effective only if the Secretary \n        certifies to Congress that there is no reasonable likelihood \n        that the implementation of this section would pose any \n        appreciable additional risk to the public health or safety.\n            ``(2) Regulations.--Notwithstanding the failure of the \n        Secretary to make a certification under paragraph (1), the \n        Secretary, not later than 30 days after the date of enactment \n        of this paragraph, shall commence a rulemaking for the purpose \n        of formulating regulations to enable the Secretary to implement \n        this section immediately upon making such a certification.''.\n    (d) Repeal of Sunset Provision.--Section 804 of the Federal Food, \nDrug, and Cosmetic Act (21 U.S.C. 384) is amended by striking \nsubsection (m).\n    (e) Authorization of Appropriations.--Section 804 of the Federal \nFood, Drug, and Cosmetic Act (21 U.S.C. 384) (as amended by subsection \n(d)) is amended by adding at the end the following:\n    ``(m) Authorization of Appropriations.--There are authorized to be \nappropriated for fiscal year 2002 and each subsequent fiscal year such \nsums as are necessary to carry out this section.''."
}